Stay updated on AGN-150998 in AMD Clinical Trial
Sign up to get notified when there's something new on the AGN-150998 in AMD Clinical Trial page.

Latest updates to the AGN-150998 in AMD Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the completed Phase 2 study record evaluating AGN-150998 and ranibizumab for exudative age-related macular degeneration, including its design, outcomes, eligibility criteria, and study locations.SummaryDifference58%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The clinical trial record remains inaccessible behind a 403 error.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision number was updated from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating access to the study record is blocked. The new content includes a minimal header and a Home button, plus a revision banner (Revision: v3.7.0), reflecting a site-wide template update rather than substantive study data.SummaryDifference19%

Stay in the know with updates to AGN-150998 in AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AGN-150998 in AMD Clinical Trial page.